Table 1.
Characteristics of the Study Cohorts (N=1724 Per Group)
| RYGB (n=1724) | Control (n=1724) | P Value | |
|---|---|---|---|
| Used in matching criteria | |||
| Age, y—mean (SD) | 45.0 (10.6) | 45.1 (10.6) | 0.986a |
| Sex | |||
| Female, % (n) | 87% (n=1493) | 87% (n=1493) | NA |
| Male, % (n) | 13% (n=231) | 13% (n=231) | |
| BMI, kg/m2—mean (SD) | 46.5 (6.0) | 46.5 (6.1) | 0.930a |
| Diabetes mellitus, % (n) | 28% (n=486) | 28% (n=486) | NA |
| 10‐y CVD risk (FRS), %—mean (SD) | 9.40 (8.11) | 9.35 (8.05) | 0.851a |
| Smoking history | |||
| Ever, % (n) | 42% (n=724) | 42% (n=724) | NA |
| Never, % (n) | 58% (n=1000) | 58% (n=1000) | |
| Anti‐HTN med. use, % (n) | 64% (n=1097) | 64% (n=1097) | NA |
| Other items within FRS | |||
| Systolic BP, mm Hg—median (IQR) | 128 (120, 140) | 128 (121, 134) | 0.100b |
| Cholesterol, mg/dL—median (IQR) | 183 (161, 210) | 186 (165, 209) | 0.062b |
| HDL, mg/dL—median (IQR) | 46 (39, 54) | 46 (40, 53) | 0.392b |
| Other patient characteristics | |||
| Race | |||
| White, % (n) | 96% (n=1656) | 97% (n=1669) | 0.581c |
| Black, % (n) | 2% (n=35) | 2% (n=26) | |
| Hispanic, % (n) | 2% (n=28) | 1% (n=23) | |
| Other, % (n) | <1% (n=5) | <1% (n=6) | |
| Diastolic BP, mm Hg—median (IQR) | 78 (70, 82) | 78 (74, 81) | <0.0001b |
| Statin use, % (n) | 31% (n=534) | 32% (n=547) | 0.633c |
Anti‐HTN medications included ACE inhibitors, β‐blockers, diuretics, thiazides, calcium channel blockers, and angiotensin II receptor antagonists. Median follow‐up time=5.7 years, range=[0.1, 12.0]. ACE indicates angiotensin‐converting enzyme; BMI, body mass index; CVD, cardiovascular disease; FRS, Framingham Risk Score; HDL, high‐density lipoprotein; HTN, hypertension; IQR, interquartile range;. NA, not applicable; RYGB, Roux‐en‐Y gastric bypass.
a
Two‐sample t test.
b
Wilcoxon rank sum test.
c
χ2 test.